Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France

AIDS

Volumn 23, Issue 6, 2009, Pages 717-724

  Chaix, Marie Laure ^a,m   Descamps, Diane ^b   Wirden, Marc ^c   Bocket, Laurence ^d   Delaugerre, Constance ^e   Tamalet, Catherine ^f   Schneider, Veronique ^g   Lzopet, Jacques ^h   Masquelier, Bernard ⁱ   Rouzioux, Christine ^a   Meyer, Laurence ^j   Costagliola, Dominique ^j,k,l  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f TIMONE HOSPITAL   (France)

^g HÔPITAL TENON   (France)

^h CHU PURPAN   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j INSERM   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Drug resistance; Epidemiology; France; HIV 1 primary infection; Subtype

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; DISEASE SURVEILLANCE; FEMALE; FRANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; PRIMARY INFECTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 64649101845     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328326ca77     Document Type: Article

References (37)

1. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729-733.
2. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
3. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
4. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-1088.
5. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135-1141.
6. Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000; 16:429-434.
7. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
8. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-F23.
9. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.J Acquir Immune Defic Syndr 2005; 40:505-511.
10. Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17:2635-2643.
11. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2 005,331:1368.
12. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004; 18:1571-1577.
13. Routy JP, Machouf N, Edwardes MD, Brenner BG, Thomas R, Trottier B, et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS 2004; 18:2305-2312.
14. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16:1511-1519.
15. Wensing AM, Boucher CA. Worldwide transmission of drug- resistant HIV. AIDS Rev 2003; 5:140-155.
16. Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, et al. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 2002; 16:793-796.
17. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, Deveau C, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001 -2002.J Acquir Immune Defic Syndr 2005; 38:545-552.
18. Chaix ML, Deveau C, Calvez V, Cottalorda J, Delamarre C, Delaugerre C, et al. Increase of non-B HIV-1 resistant virus in primary infected patients: 9 years of French experience (1996- 2004). Antivir Ther 2006; 11:S1-S123.
19. Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D, et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis 2007; 196:377- 383.
20. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709-715.
21. Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78:153-160.
22. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215- 223.
23. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673- 4680.
24. Felsenstein J. An alternating least squares approach to inferring phytogenies from pairwise distances. Syst Biol 1997; 46:101- 111.
25. Deshpande A, Jauvin V, Magnin N, Pinson P, Faure M, Masquelier B, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007; 23:335-340.
26. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Paris: Médecine- Sciences Flammarion; 2008.
27. Vidal N, Frange P, Chaix ML, Mulanga C, Lepira F, Bazepeo SE, et al. Characterization of an old complex circulating recombinant form, CRF27-cpx, originating from the Democratic Republic of Congo (DRC) and circulating in France. AIDS Res Hum Retroviruses 2008; 24:315-321.
28. Frange P, Galimand J, Vidal N, Goujard C, Deveau C, Souala F, et al. New and old complex recombinant HIV-1 strains among patients with primary infection in 1996-2006 in France: the French ANRS CO06 primo cohort study. Retrovirology 2008; 5:69.
29. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
30. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21:2223-2229.
31. Fox J, Hill S, Kaye S, Dustan S, McClure M, Fidler S, Mackie NE. Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment- naive individuals. AIDS 2007; 21:237-239.
32. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
33. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21:1035-1039.
34. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/ early HIV-1 infection. J Infect Dis 2007; 195:951-959.
35. Chaix ML, Galimand J, Frange P, Deveau C, Wirden M, Signori-Schmuck A, et al. Are Patients with Acute HIV-1 Infection the Major Source of HIV Transmission in France? A 5 Year Survey in the ANRS PRIMO Network. Antivir Ther 2008; 13:S3; 136.
36. Holguin A, Alvarez A, Soriano V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 2002; 16: 1163-1170.
37. Boni J, Pyra H, GebhardtM, Perrin L, Burgisser P, Matter L, etal. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr 1999; 22:174-179.